Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Active, not recruiting · NCT02062827 · Registry updated 2025-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma | Infections, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, gliosarcoma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor, viral infectious disease | Active, not recruiting | Phase 1 | 2025-10-02 | NCT02062827 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
| University of Alabama at Birmingham | 467 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | United States | 247 |